One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
June 17, 2023 17:30 ET
|
Ascendis Pharma
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the...
Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
June 13, 2023 07:00 ET
|
Ascendis Pharma
- Endocrinology clinical development progress and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted - Phase 3 Week 52 data for...
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice...
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
June 05, 2023 17:30 ET
|
Ascendis Pharma
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism COPENHAGEN,...
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
May 31, 2023 08:30 ET
|
Ascendis Pharma
– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells – TransCon...
Ascendis Pharma to Host Oncology Program Update on May 31
May 25, 2023 08:30 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday,...
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
May 13, 2023 19:00 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth...
Ascendis Pharma to Participate in the BofA Securities 2023 Health Care Conference
May 03, 2023 16:15 ET
|
Ascendis Pharma
COPENHAGEN, Denmark, May 03, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice...
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism
May 01, 2023 07:00 ET
|
Ascendis Pharma
FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product No new preclinical studies, or Phase 3 clinical...
Ascendis Pharma Reports First Quarter 2023 Financial Results
April 27, 2023 16:01 ET
|
Ascendis Pharma
• Focused on bringing TransCon™ PTH to the U.S. and EU markets as soon as possible • 145 of 154 clinical trial participants continue treatment with TransCon PTH for up to 3 years, and U.S. Expanded...